Company intelligence / Profile preview

INOVIQ

Notting Hill, VIC, Australiainoviq.com ↗

Ownership: Private
Employees: ~20
Development stage: Other

Overview

INOVIQ has commercialized the EXO-NET® exosome isolation tool and the hTERT test as an adjunct to urine cytology in bladder cancer. Its pipeline includes clinical-stage blood tests for early detection/monitoring of ovarian and breast cancers, with ongoing development of exosome-based therapeutics in preclinical stages targeting solid tumors. The company has secured global distribution partnerships and expanded its IP portfolio around exosome capture/isolation technologies.

Therapeutic areas: Oncology
Modalities: Diagnostic test (for diagnostics)Exosome-based therapy (for therapeutics)
Industry: Molecular Diagnostics

Drug pipeline

2 assets

EEV-001

Preclinical

1 more asset in the full pipeline.

Partnerships

Promega Corporation – global supply/distribution agreement for EXO-NET® productsResearchDx – license/supply agreement in US market

Beyond the preview

Go deeper on INOVIQ.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INOVIQ.